Tesaro announced the launch of Varubi (rolapitant) for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Varubi was approved by the Food and Drug Administration (FDA) in September 2015.
The superior efficacy of Varubi was established in three multiple global, randomized, well-controlled, blinded Phase 3 clinical trials. Varubi, when administered in combination with a 5-HT3 receptor antagonist and dexamethasone, was significantly superior to a 5-HT3 receptor antagonist and dexamethasone in preventing delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving either moderately or highly emetogenic chemotherapy. In all 3 trials, Varubi demonstrated significant reduction in episodes of vomiting or use of rescue medication and less nausea that interfered with normal daily life.
Varubi, a selective and competitive human substance P/neurokinin 1 (NK-1) receptor antagonist, is available as a single dose pack containing two 90mg tablets.
For more information call (844) 483-7276 or visit Varubirx.com.